Compare JFIN & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFIN | STIM |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.6M | 120.4M |
| IPO Year | 2018 | 2018 |
| Metric | JFIN | STIM |
|---|---|---|
| Price | $1.44 | $3.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 60.5K | ★ 1.4M |
| Earning Date | 06-03-2026 | 05-05-2026 |
| Dividend Yield | ★ 17.47% | N/A |
| EPS Growth | N/A | ★ 57.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $52,776,000.00 |
| Revenue This Year | N/A | $11.10 |
| Revenue Next Year | N/A | $11.92 |
| P/E Ratio | $1.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $0.80 |
| 52 Week High | $11.77 | $3.44 |
| Indicator | JFIN | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 19.67 | 61.70 |
| Support Level | N/A | $1.21 |
| Resistance Level | $2.55 | N/A |
| Average True Range (ATR) | 0.16 | 0.18 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 2.26 | 72.90 |
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.